FRANCISCO JAVIER
SALMERÓN ESCOBAR
Chercheur dans le période 2002-2020
José Luis
Calleja Panero
Publications dans lesquelles il/elle collabore avec José Luis Calleja Panero (17)
2022
-
Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study
Gastroenterologia y Hepatologia, Vol. 45, Núm. 5, pp. 342-349
2021
-
Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry
Journal of Hepatology, Vol. 75, Núm. 1, pp. 86-97
2020
-
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
Antiviral Research, Vol. 174
-
Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology
-
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25
2019
-
Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort
Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 55-64
-
Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort
Liver International, Vol. 39, Núm. 1, pp. 90-97
2018
-
Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C
Journal of Hepatology, Vol. 68, Núm. 5, pp. 940-948
-
The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity
Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 11-12, pp. 1260-1270
2017
-
Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study
World Journal of Gastroenterology, Vol. 23, Núm. 41, pp. 7459-7469
-
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry
Hepatology, Vol. 65, Núm. 6, pp. 1810-1822
2015
-
Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection
Genes and Immunity, Vol. 16, Núm. 5, pp. 297-300
-
Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery
Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153
2014
-
Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study
Gastroenterologia y Hepatologia, Vol. 37, Núm. 1, pp. 1-8
2009
-
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin
Hepatology, Vol. 50, Núm. 6, pp. 1702-1708
2006
-
Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B
Alimentary Pharmacology and Therapeutics, Vol. 23, Núm. 3, pp. 409-419